Chen Yunching
Institute of Biomedical Engineering and Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, Hsinchu 30013, Taiwan; Department of Chemistry, National Tsing Hua University, Hsinchu 30013, Taiwan.
J Control Release. 2023 Apr;356:14-25. doi: 10.1016/j.jconrel.2023.02.016. Epub 2023 Feb 28.
Over the past decade, immunotherapy aiming to activate an effective antitumor immune response has ushered in a new era of cancer treatment. However, the efficacy of cancer immunotherapy is limited by low response rates and high systemic toxicity. Nanotechnology is an encouraging platform for the development of next-generation cancer immunotherapy to effectively treat advanced cancer. Nanotechnology-enabled immunotherapy has remarkable advantages, ranging from the increased bioavailability and stability of immunotherapeutic agents to the enhanced activation of immune cells and favorable safety profiles. Nanotechnology-enabled immunotherapy can target solid tumors through reprogramming or stimulating immune cells (i.e., nanovaccines); modulating the immunosuppressive tumor microenvironment; or targeting tumor cells and altering their responses to immune cells to generate effective antitumor immunity. In this Oration, I introduce the advanced strategies currently being pursued by our laboratory and other groups to improve the therapeutic efficacy of cancer immunotherapy and discuss the potential challenges and future directions.
在过去十年中，旨在激活有效的抗肿瘤免疫反应的免疫疗法开创了癌症治疗的新时代。然而，癌症免疫疗法的疗效受到低反应率和高全身毒性的限制。纳米技术是开发下一代癌症免疫疗法以有效治疗晚期癌症的一个令人鼓舞的平台。基于纳米技术的免疫疗法具有显著优势，从提高免疫治疗药物的生物利用度和稳定性到增强免疫细胞的激活以及良好的安全性。基于纳米技术的免疫疗法可以通过重新编程或刺激免疫细胞（即纳米疫苗）；调节免疫抑制性肿瘤微环境；或靶向肿瘤细胞并改变它们对免疫细胞的反应来产生有效的抗肿瘤免疫力，从而靶向实体瘤。在本次演讲中，我介绍了我们实验室和其他团队目前正在采用的先进策略，以提高癌症免疫疗法的治疗效果，并讨论潜在的挑战和未来方向。
